Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 7, 2025.

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.